Recombinant Human Endostatin, an angiogenesis inhibitor
, was developed by a Chinese enterprise in 1999 and approved by the China Food and Drug Administration (CFDA) in 2005 to be used in the combination chemotherapy for the recurrence and metastasis of NSCLC.
Rivoceranib, also known as apatinib or Aitan (brand name) in China, is the first successful small-molecule angiogenesis inhibitor
in gastric cancer.
A poster titled "Enhancement of anti-PD-1 antitumor efficacy in syngeneic preclinical models by the angiogenesis inhibitor
lucitanib" was presented Monday and shows that lucitanib combined with an anti-PD-1 agent enhances the anti-tumor activity of either single agent in multiple syngeneic animal models.
Semaphorin-3B is an angiogenesis inhibitor
that is inactivated by furin-like pro-protein convertases.
New data from Boehringer Ingelheim's Phase IINVICTAN-1 study show that BI 695502, its bevacizumab biosimilar candidate, is bioequivalent to Roche's Avastin, an angiogenesis inhibitor
used to treat a variety of cancers and marketed in the U.S.
Shing et al., "Angiostatin: a novel angiogenesis inhibitor
that mediates the suppression of metastases by a Lewis lung carcinoma," Cell, vol.
Galectin-1 was interestingly recently found to be the target of the potent angiogenesis inhibitor
In this report, we determined the antitumor and antiangiogenesis activities of lenvatinib, an angiogenesis inhibitor
that targets multiple RTKs, in 11 human thyroid cancer xenograft models with 3 types of histology (DTC, MTC, and ATC).
For cancer therapeutics, the FDA approved bevacizumab (Avastin, humanized anti-VEGF monoclonal antibody), an angiogenesis inhibitor
, to treat metastatic colorectal cancer in 2004 .
Hayes et al., "A Phase I study of the angiogenesis inhibitor
SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points," British Journal of Cancer, vol.
The approval of bevacizumab, the angiogenesis inhibitor
marketed as Avastin, as a treatment for metastatic breast cancer is being withdrawn by the Food and Drug Administration, the agency announced.
But bevacizumab was effective only when used both as an adjunct to chemotherapy and as maintenance therapy: Women who received the angiogenesis inhibitor
with chemotherapy but got a placebo during the maintenance phase had a median progression-free survival of 11.2 months, which was not significantly better than that of women who received chemotherapy and placebo only (HR 0.98, P = .16), Dr.